Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 2/20 | 0.57 |
| ▸ | ADRB1 | P08588 | 7/20 | 0.52 |
| ▸ | ADRB3 | P13945 | 7/20 | 0.52 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | PPARG | P37231 | 1/20 | 0.45 |
| ▸ | MYC | P01106 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2912073 | 0.94 | HDAC1 (0.55) | HDAC1ADRB1ADRB3ADRB2ALDH1A1 | |
| SCHEMBL2912907 | 0.81 | MEN1 (0.57) | ADRB1ADRB3ADRB2ALDH1A1SMN1; SMN2 | |
| SCHEMBL4074391 | 0.81 | HDAC1 (0.56) | HDAC1ADRB1ADRB3ALDH1A1PPARG | |
| SCHEMBL2744942 | 0.78 | ADRB1 (0.56) | ADRB1ADRB3ADRB2 | |
| SCHEMBL2353573 | 0.77 | MAPK14 (0.54) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL2912501 | 0.76 | HDAC1 (0.52) | HDAC1ADRB1ADRB3ADRB2ALDH1A1 | |
| SCHEMBL4602270 | 0.75 | GRIK1 (0.55) | ALDH1A1 | |
| SCHEMBL2912888 | 0.75 | MAPK1 (0.55) | HDAC1PPARG | |
| SCHEMBL2744296 | 0.74 | ALDH1A1 (0.59) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL4601231 | 0.74 | PPARG (0.55) | PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1940786-B1 | BIPHENYL DERIVATIVES AND THEIR USE IN TREATING HEPATITIS C | ARROW THERAPEUTICS LTD (GB) | 2010-08-18 | — | — | EP | disclosed |
| US-20080255105-A1 | Biphenyl Derivatives and Their Use in Treating Hepatitis C | ARROW THERAPEUTICS LIMITED (GB) | 2008-10-16 | — | — | US | disclosed |
| EP-1940786-A1 | BIPHENYL DERIVATIVES AND THEIR USE IN TREATING HEPATITIS C | Arrow Therapeutics Limited (GB) | 2008-07-09 | — | — | EP | disclosed |
| WO-2007031791-A1 | BIPHENYL DERIVATIVES AND THEIR USE IN TREATING HEPATITIS C | ARROW THERAPEUTICS LIMITED (GB) | 2007-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255105-A1 | Biphenyl Derivatives and Their Use in Treating Hepatitis C | NR4A1, NR0B1, NR1H4 | HDAC1 2583/4885ADRB1 133/4885ADRB3 310/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.